Shukra Pharmaceuticals Ltd has received a Letter of Intent from the Yamuna Expressway Industrial Development Authority (YEIDA) for a 10-acre land allotment at the Medical Device Park, Sector 28, Greater Noida, with a planned investment of nearly ₹600 crore. The new facility will focus on manufacturing next-generation surgical robotics and Boron Neutron Capture Therapy (BNCT) systems, positioning India as a key hub for advanced medical devices, robotic surgery, and cancer treatment technologies.
The project is expected to create over 900 direct jobs and nearly 2,000 indirect employment opportunities, significantly strengthening India’s medical technology manufacturing ecosystem and supporting the government’s Atmanirbhar Bharat and Make in India initiatives.
In a major boost to India’s healthcare innovation landscape, Shukra Pharmaceuticals has also signed a Memorandum of Understanding (MoU) with Borns Medical Robotics Inc. The partnership will introduce the AI-powered Veer Surgical Robot, a cutting-edge robotic surgery platform designed to deliver high precision, enhanced safety, and improved patient outcomes at a more affordable cost.
Dr. Minakshi Late, CEO and Global Head of Shukra Pharmaceuticals, highlighted the national importance of the initiative, stating that the collaboration aims to make advanced robotic surgery accessible across India, particularly in underserved and non-metro regions. Dr. Alexander T. Teichmann, Chief Medical Officer at Borns Medical Robotics, added that the partnership combines AI-driven robotics with scalable healthcare infrastructure to standardize surgical outcomes across India and Asia.
The Veer Surgical Robot features advanced capabilities such as single-port surgery, AI-based safety mechanisms, and precision micro-instruments. Clinical trials have demonstrated strong safety and efficacy results, with findings published in leading international medical journals and reported to CDSCO.
By establishing manufacturing, training, and distribution capabilities in India, Shukra Pharmaceuticals aims to expand access to minimally invasive, robotic-assisted surgery across tier-2 and tier-3 cities—making high-quality, affordable healthcare a reality for millions.
